Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
11th November 2020 | Carl Goldfischer | 5,000 | Open or private purchase | $12.07 | $60,350.00 |
16th March 2020 | Carl Goldfischer | 690,232 | Conversion of derivative | $0.00 | |
16th March 2020 | Carl Goldfischer | 13,148 | Conversion of derivative | $0.00 | |
10th October 2019 | Sujal Shah | 5,000 | Open or private purchase | $4.30 | $21,500.00 |
23rd September 2019 | Sujal Shah | 3,100 | Open or private purchase | $5.55 | $17,205.00 |
20th September 2019 | Sujal Shah | 1,900 | Open or private purchase | $5.50 | $10,450.00 |
7th February 2019 | Carl Goldfischer | 2,335 | Exercise of derivative | $5.00 | $11,675.00 |
7th February 2019 | Carl Goldfischer | 9,340 | Exercise of derivative | $5.50 | $51,370.00 |
7th February 2019 | Carl Goldfischer | 11,675 | Open or private sale | $9.02 | $105,328.35 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company. Its products include MBX-8025 and Arhalofenate. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
17th November 2020
14th November 2020
11th November 2020
8th November 2020